Same Indication

Nivolumab vs Sumatriptan

Nivolumab vs Sumatriptan: Overview

This comparison examines the pharmacological differences between Nivolumab and Sumatriptan.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Sumatriptan: Selective 5-HT1B/1D receptor agonist.

Pharmacokinetics

Half-life: Nivolumab — 27 days; Sumatriptan — 2.5 hours.

Chemical Properties

Molecular Formula: Sumatriptan — C14H21N3O2S.

Molecular Weight: Sumatriptan — 295.4020 g/mol.

Type: Nivolumab — Antibody; Sumatriptan — Small molecule.